Asensus Surgical Q2 2024 Adj. EPS $(0.07) Misses $(0.06) Estimate, Sales $2.207M Beat $1.231M Estimate
Portfolio Pulse from Benzinga Newsdesk
Asensus Surgical (AMEX:ASXC) reported Q2 2024 adjusted EPS of $(0.07), missing the $(0.06) estimate, but achieved sales of $2.207M, beating the $1.231M estimate. EPS improved by 22.22% YoY, and sales increased by 104.16% YoY.
August 13, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Asensus Surgical reported Q2 2024 adjusted EPS of $(0.07), missing the $(0.06) estimate, but achieved sales of $2.207M, beating the $1.231M estimate. EPS improved by 22.22% YoY, and sales increased by 104.16% YoY.
Despite missing EPS estimates, Asensus Surgical showed significant improvement in both EPS and sales YoY. The strong sales performance, beating estimates by 79.29%, is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100